SYK at a glance
Stryker Corporation (SYK, SEC CIK 310764) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on October 6, 2026 and Form 4 insider filings as recently as September 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Stryker Corporation (SYK) reported revenue of $25.1 billion (up 11.2% from FY2024) and net income of $3.2 billion. Diluted EPS was $8.40.
- As of June 30, 2026, 60 institutional investment managers tracked by SignalX reported holding Stryker Corporation (SYK) shares worth $45.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Crotty Dylan Bram on August 21, 2026 of 441 shares at $328.61 per share.
- In the last 90 days, SYK insiders reported 0 open-market purchases ($0) and 22 open-market sales ($118.2M) on Form 4, a net sale of $118.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $25.1B
- +11.2% vs prior year
- Insiders · 90 days
- 0 buys · 22 sells
- Net −$118.2M
- 13F holders
- 60 funds
- $45.1B · +1 vs prior quarter
- Latest 8-K
- Jul 30, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- Regulatory risk: EU medical device regulations require costly quality system updates, labeling changes, and remanufacturing impacting R&D and compliance expenses in 2025
- Geopolitical/macroeconomic risk: Foreign currency fluctuations affected net sales by ±0.5%, with 10.7% growth in constant currency highlighting sensitivity to exchange rates
- Operational risk: Inventory stepped up to fair value increased amortization expenses by $173M in 2025, reflecting acquisition integration supply chain complexity
- Competitive risk: Sales growth slowdown in Orthopaedics segment (4.3% in 2025 vs 8.9% in 2024) signals risk from market competition affecting higher-margin segment
- Financial risk: Increased interest expense to $607M in 2025 due to $3.0B revolving credit facility and $3.0B commercial paper limit raising leverage and refinancing needs
Business Overview
- Core business model focused on medical technology and device manufacturing, emphasizing innovation and compliance
- No new products, services, or segments explicitly introduced or emphasized in the 2026 filing
- Continued adherence to corporate governance enhancements, including adoption of updated Insider Trading Policies and transparency practices
- Equity compensation plans with 36.5 million shares authorized for issuance, including 11.2 million options outstanding at $234.56 average exercise price
- Noteworthy emphasis on proxy statement incorporation by reference for governance, compensation, and related-party matters instead of detailed disclosures within the filing
Management Discussion & Analysis
- Revenue $18.0B, up 9% YoY driven by MedSurg and Neurotechnology segment growth
- Operating margin 22.5% vs 21.0% YoY due to product mix and cost management
- MedSurg and Neurotechnology segment revenue $11.2B up 12%, Orthopaedics $6.8B up 4%
- Cash flow from operations $3.2B; capital allocation: $1.0B acquisitions, $0.5B dividends, $0.8B share repurchases
- Management highlights risks from tariffs, inflation, and geopolitical issues impacting costs and demand
AI summary of the SYK 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $6,589M, up 9.4% YoY from $6,022M
- Operating margin 25.2% vs 18.5% YoY; gross margin 68.3% vs 63.8%
- Best segment Medical revenue $1,122M, up 13.4%; worst Vascular revenue $496M, down 0.7%
- Operating income $1,659M vs $1,113M; net earnings $1,276M vs $884M
- Outlook: MedSurg and Neurotechnology growth expected to outpace Orthopaedics, creating unfavorable segment-mix pressure
Risk Factors
- No risk-factors section provided in the filing excerpt
- No quarter-specific changes identifiable versus the most recent 10-K
- Excerpt contains equity issuance, repurchase authorization, and executive trading disclosures only
AI summary of the SYK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Stryker reported second-quarter 2026 operating results on July 30, 2026
- Detailed financial results and management commentary are contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 net sales $6.6B, up 9.4%; organic growth 9.0%, indicating broad volume-driven demand
- Adjusted operating margin 27.4%, up 170 bps; adjusted EPS $3.69, up 17.9%
Item 8.01: Other Events
- Stryker reorganized reporting, combining orthopaedic instruments, Mako, power tools, and enabling technologies into new Ortho Tech operations
- Two reportable segments remain: MedSurg and Neurotechnology, and Orthopaedics
AI summaries of SYK 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SYK
Don't miss the next SYK filing
- Alerts as it files. A push when SYK files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SYK, by share count.
- Ask anything. An AI agent that reads every SYK filing and answers with sources.
SYK alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Wells Preston Wendell | J | Sep 24, 2026 | 109 | - |
| Wells Preston Wendell | J | Sep 22, 2026 | 962 | - |
| Crotty Dylan Bram | Sell | Aug 21, 2026 | 441 | $328.61 |
| STRYKER RONDA E | Sell | Aug 19, 2026 | 16,612 | $340.71 |
| STRYKER RONDA E | Sell | Aug 19, 2026 | 11,257 | $338.90 |
| STRYKER RONDA E | Sell | Aug 19, 2026 | 10,812 | $339.71 |
| STRYKER RONDA E | Sell | Aug 19, 2026 | 320 | $336.79 |
| STRYKER RONDA E | Sell | Aug 19, 2026 | 440 | $333.18 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $22.6B | $25.1B |
| Gross Profit | - | $14.4B | $16.1B |
| Operating Income | - | $3.7B | $4.9B |
| Net Income | - | $3.0B | $3.2B |
| Gross Margin | - | 63.9% | 64.0% |
| Op. Margin | - | 16.3% | 19.5% |
| Net Margin | - | 13.2% | 12.9% |
| Balance Sheet | |||
| Total Assets | $39.9B | $43.0B | $47.8B |
| Equity | $18.6B | $20.6B | $22.4B |
| ROE | - | 14.5% | 14.5% |
| Per Share | |||
| EPS | - | $7.76 | $8.40 |
| Cash Flow | |||
| Operating CF | - | $4.2B | $5.0B |
| CapEx | - | $755.0M | $761.0M |
Source: XBRL data in Stryker Corporation (SYK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SYK share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 60 | $45.06B |
| Q1 2026 | 59 | $45.49B |
| Q4 2025 | 57 | $47.74B |
| Q3 2025 | 62 | $56.45B |
| Q2 2025 | 61 | $56.59B |
| Q1 2025 | 56 | $39.05B |
| Q4 2024 | 53 | $28.97B |
| Q3 2024 | 48 | $13.86B |
- T. Rowe Price Group+1.88M (+19%)
- Ameriprise Financial+1.87M (+133%)
- JPMorgan Chase & Co+1.66M (+11%)
- Bank of America Corp+346.6K (+8%)
- Citigroup+238.4K (+62%)
- FMR LLC (Fidelity)−662.0K (-28%)
- AQR Capital Management−496.0K (-51%)
- Two Sigma Investments−456.2K (-97%)
- BNY Mellon−403.9K (-10%)
- Morgan Stanley−336.8K (-5%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 456 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SYK filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 6, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 10-Q | Jul 31, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 8-K | May 20, 2026 | - | Analysis | |
| 4 | May 12, 2026 | - | - | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 8-K | May 8, 2026 | - | Analysis | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
SYK SEC filings: frequently asked questions
Are SYK insiders buying or selling?
In the last 90 days, Stryker Corporation (SYK) officers, directors and 10% owners reported no open-market purchases and 22 open-market sales worth $118.2 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SYK stock?
As of June 30, 2026, the largest Stryker Corporation (SYK) holders among the 13F filers tracked by SignalX were BlackRock ($8.6 billion), Vanguard Capital Management LLC ($7.1 billion), JPMorgan Chase & Co ($5.7 billion), State Street Corp ($4.9 billion), T. Rowe Price Group ($3.8 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SYK's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Stryker Corporation (SYK) reported revenue of $25.1 billion (up 11.2% from FY2024) and net income of $3.2 billion. Diluted EPS was $8.40. The figures come from the XBRL data in the 10-K.
What are the main risks in SYK's latest 10-K?
In the 10-K filed February 11, 2026, Stryker Corporation (SYK) flagged: Regulatory risk: EU medical device regulations require costly quality system updates, labeling changes, and remanufacturing impacting R&D and compliance expenses in 2025. Geopolitical/macroeconomic risk: Foreign currency fluctuations affected net sales by ±0.5%, with 10.7% growth in constant currency highlighting sensitivity to exchange rates. (AI summary of the Risk Factors section.)
What did SYK report in its latest 8-K?
Stryker Corporation (SYK) filed an 8-K on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Stryker reported second-quarter 2026 operating results on July 30, 2026.
What are the latest SYK SEC filings?
Stryker Corporation (SYK) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on October 6, 2026 and a Form 4 insider filing on September 28, 2026.
What is SYK's SEC CIK number?
Stryker Corporation (SYK)'s SEC Central Index Key (CIK) is 310764. EDGAR lists every SYK filing under that number.
Ask anything about SYK
The research agent reads SYK's filings, financials, insider trades and 13F holders, then answers with sources.